Wcn24-461 Rapid Complement Inhibition With the C5 Inhibitor Crovalimab: Timing Analysis Using Animal Model and Composer Trial Data

Atypical hemolytic uremic syndrome (aHUS) is currently treated with the complement C5 antibodies eculizumab and ravulizumab. Although effective at inhibiting complement-mediated thrombotic microangiopathy (TMA) and improving renal function, regular intravenous (IV) infusion dosing regimens can be burdensome, particularly in pediatric patients (pts). Crovalimab (crova) is a novel C5 antibody, engineered for small volume subcutaneous (SC) self-injection every 4 weeks (Q4W), in a weight-based dosing regimen.